137 related articles for article (PubMed ID: 7919239)
1. Estimation of chronic phase duration in Ph-positive chronic myelocytic leukemia treated with busulfan: statistical analysis on Japanese patients.
Hashimoto T; Ohtaki M; Ueoka H; Munaka M; Kuramoto A; Kamada N
Int J Hematol; 1994 Jul; 60(1):59-69. PubMed ID: 7919239
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
[TBL] [Abstract][Full Text] [Related]
3. [Multivariate analysis of prognostic factors influencing survival in chronic myelogenous leukemia].
Sakamoto S; Kurata H; Miwa A
Rinsho Ketsueki; 1989 Aug; 30(8):1180-4. PubMed ID: 2601030
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
[TBL] [Abstract][Full Text] [Related]
5. [Allogeneic bone marrow transplantation in chronic myeloid leukemia. The clinical results and risk factors in 70 patients].
Tomás JF; Peñarrubia MJ; García JA; Figuera A; Gómez-García de Soria V; Steegmann JL; Arranz R; Cámara R; Gabriel R; Vázquez L
Med Clin (Barc); 1995 Nov; 105(16):605-11. PubMed ID: 8523939
[TBL] [Abstract][Full Text] [Related]
6. [A trial for prolongation of chronic phase of chronic myeloid leukemia--maintenance of leukocyte counts within normal range with busulfan].
Matsuo T; Tomonaga M; Kuriyama K; Jinnai I; Jubashi T; Nonaka H; Kohno T; Tsukasaki K; Atogami S; Itoyama T
Rinsho Ketsueki; 1989 May; 30(5):625-30. PubMed ID: 2795875
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia.
Onida F; Ball G; Kantarjian HM; Smith TL; Glassman A; Albitar M; Scappini B; Rios MB; Keating MJ; Beran M
Cancer; 2002 Oct; 95(8):1673-84. PubMed ID: 12365015
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.
Cervantes F; Hernández-Boluda JC; Steegmann JL; Conde E; Alvarez-Larrán A; López-Jiménez J; Osorio S; Villalón L; Camós M; García-Conde J; Odriozola J
Haematologica; 2003 Oct; 88(10):1117-22. PubMed ID: 14555307
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
[TBL] [Abstract][Full Text] [Related]
10. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia.
Carella AM; Chimirri F; Podestà M; Pitto A; Piaggio G; Dejana A; Lerma E; Pollicardo N; Vassallo F; Soracco M; Benvenuto F; Valbonesi M; Carlier P; Vimercati R; Prencipe E; Gatti AM; Ferrara RA; Incagliato M; Florio G; Frassoni F
Bone Marrow Transplant; 1996 Feb; 17(2):201-5. PubMed ID: 8640167
[TBL] [Abstract][Full Text] [Related]
11. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of chronic myeloid leukemia using alpha-interferon and hydroxyurea. Study of 30 cases].
Nese M; de Bellis R; Urtiarte R; Di Landro J
Sangre (Barc); 1994 Jun; 39(3):183-6. PubMed ID: 7940047
[TBL] [Abstract][Full Text] [Related]
13. [Parameters significant for the prognosis of chronic myeloid leukemia in the chronic phase].
Maras J; Ribicić I; Maras-Simunić M; Skare L
Acta Med Iugosl; 1990; 44(4):389-97. PubMed ID: 2091442
[TBL] [Abstract][Full Text] [Related]
14. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response.
Palandri F; Iacobucci I; Soverini S; Castagnetti F; Poerio A; Testoni N; Alimena G; Breccia M; Rege-Cambrin G; Tiribelli M; Varaldo R; Abruzzese E; Martino B; Luciano L; Pane F; Saglio G; Martinelli G; Baccarani M; Rosti G
Clin Cancer Res; 2009 Feb; 15(3):1059-63. PubMed ID: 19188180
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study.
Farag SS; Ruppert AS; Mrózek K; Carroll AJ; Pettenati MJ; Le Beau MM; Peterson BL; Powell BL; Ozer H; Silver RT; Larson RA; Bloomfield CD;
Int J Oncol; 2004 Jul; 25(1):143-51. PubMed ID: 15201999
[TBL] [Abstract][Full Text] [Related]
17. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
18. The negative prognostic impact of derivative 9 deletions in patients who received hydroxyurea treatment for chronic myelogenous leukemia in the chronic phase.
Li JY; Xu W; Wu W; Zhu Y; Qiu HR; Zhang R; Zhang SJ; Qian SX
Onkologie; 2008 Nov; 31(11):585-9. PubMed ID: 19145090
[TBL] [Abstract][Full Text] [Related]
19. [Chronic myeloid leukemia].
Hehlmann R
Ther Umsch; 1996 Feb; 53(2):82-7. PubMed ID: 8629268
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide.
Galimberti M; Polchi P; Lucarelli G; Angelucci E; Baronciani D; Giardini C; Gaziev D; Erer B; Ripalti M; Rapa S
Bone Marrow Transplant; 1994 Feb; 13(2):197-201. PubMed ID: 8205089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
